Tests personalised repurposed drug combinations for advanced thyroid cancer
Tests drug combinations chosen from tumour genetics in adults with advanced thyroid cancer.
Plain-language title generated from the registry record
Registry title: Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
Key facts
- Where
- Nijmegen, NetherlandsSee the site
- Phase
- Phase 1
Where in Netherlands
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Radboud University Medical Center
- Trial code
- NCT07485569EU 2023-507214-28-00
- Record updated
- 28 October 2026
- Original description
This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.Read full original descriptionShow less
Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial
This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.
Inclusion: Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available; Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0); Measurable disease per RECIST 1.1; ECOG performance status ≤ 2; Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.
Exclusion: Other active malignancies requiring therapy; Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory); Neutropenia (ANC < 1.5 × 10⁹/L); Inability to provide informed consent; Inability to obtain a (new) biopsy for molecular profiling; Pregnancy or breastfeeding.